Adaptive Biotechnologies: Funding, Investors & Team (Oct 2026)
Adaptive Biotechnologies is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clone-SEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers. It was founded in 2009 and headquartered in Seattle, Washington.
Adaptive Biotechnologies has raised $125M across 2 funding rounds on record, the most recent a Post-IPO Debt of $125M announced in Sep 2022.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Adaptive Biotechnologies Company Profile and Key Stats
Latest funding round on record: Sep 2022.
Adaptive Biotechnologies Funding Rounds
Adaptive Biotechnologies raised $100k in a Post-IPO Equity announced in Mar 2022.
6 months later, a Post-IPO Debt of $125M was announced in Sep 2022.
Adaptive Biotechnologies Founders and Leadership Team
No contact details are on record for this team yet.
Adaptive Biotechnologies Funding Compared to Other Biotechnology Startups
Adaptive Biotechnologies' latest round of $125M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Adaptive Biotechnologies in Biotechnology and Seattle
Companies Similar to Adaptive Biotechnologies
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Adaptive Biotechnologies Funding FAQs
What does Adaptive Biotechnologies do?
Adaptive Biotechnologies is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clone-SEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers. It was founded in 2009 and headquartered in Seattle, Washington.
How much funding has Adaptive Biotechnologies raised?
Adaptive Biotechnologies has raised $125M across 2 rounds on record. The most recent is a Post-IPO Debt of $125M announced in Sep 2022.
When did Adaptive Biotechnologies last raise funding?
Adaptive Biotechnologies' most recent funding round on record is a Post-IPO Debt of $125M, announced in Sep 2022.
Who founded Adaptive Biotechnologies?
FundedIQ lists Harlan Robins (Founder) at Adaptive Biotechnologies.
Who is the CEO of Adaptive Biotechnologies?
Chad Robins is listed as CEO at Adaptive Biotechnologies.
Where is Adaptive Biotechnologies headquartered?
Adaptive Biotechnologies is based in Seattle, Washington, United States.
How many employees does Adaptive Biotechnologies have?
Adaptive Biotechnologies is in the 501-1000 employee band.
How does Adaptive Biotechnologies' funding compare to other Biotechnology startups?
Adaptive Biotechnologies' latest round of $125M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Adaptive Biotechnologies Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Adaptive Biotechnologies is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.